In HCC cells, LPAR6 mediates the resistance to sorafenib by promoting lactic acid fermentation at the expense of oxidative phosphorylation, and treatment with 9-xanthenyl acetate (XAA), a LPAR6 antagonist, can overcome this resistance [186]. The gene discussed is LPAR6; the disease is hepatocellular carcinoma.